In vitro Toxicology: Bringing the In Silico and In Vivo Worlds Closer

Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals

Volumn , Issue , 2006, Pages 21-32

  Xu, Jinghai J ^a  

^a PFIZER INC   (United States)

Author keywords

"Failure prediction" in pharmaceutical discovery; In silico toxicology and in vitro toxicological outcomes; In vitro toxicology

Indexed keywords

EID: 50449101041     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470145890.ch2     Document Type: Chapter

References (56)

1. Schuster D, Laggner C, Langer T. Why drugs fail-A study on side effects in new chemical entities. Curr Pharm Des 2005;11:3545-59.
2. White AC, Mueller RA, Gallavan RH, Aaron S, Wilson AG. A multiple in silico program approach for the prediction of mutagenicity from chemical structure. Mutat Res 2003;539:77-89.
3. Snyder RD, Pearl GS, Mandakas G, Choy WN, Goodsaid F, Rosenblum IY. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules. Environ Mol Mutagen 2004;43:143-58.
4. Car BD. Enabling Technologies in Reducing Drug Attrition Due to Safety Failures. Am Drug Discov 2006;1:53-6.
5. Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, et al. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci 2004;95:311-19.
6. Diaz GJ, Daniell K, Leitza ST, Martin RL, Su Z, McDermott JS, et al. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. J Pharmacol Toxicol Meth 2004;50:187-99.
7. Raab CE, Butcher JW, Connolly TM, Karczewski J, Yu NX, Staskiewicz SJ, et al. Synthesis of the first sulfur-35-labeled hERG radioligand. Bioorg Med Chem Lett 2006;16:1692-5.
8. Rezazadeh S, Hesketh JC, Fedida D. Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay. J Biomol Screen 2004;9:588-97.
9. Guo L, Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Meth 2005;52:123-35.
10. Pugsley MK. Methodology used in safety pharmacology: Appraisal of the state-of-the-art, the regulatory issues and new directions. J Pharmacol Toxicol Meth 2005;52:1-5.
11. Kirkland D, Aardema M, Henderson L, Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res 2005;584:1-256.
12. Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res 2000;455:29-60.
13. Miller JE, Vlasakova K, Glaab WE, Skopek TR. A low volume, high-throughput forward mutation assay in Salmonella typhimurium based on fluorouracil resistance. Mutat Res 2005;578:210-24.
14. Flamand N, Meunier J, Meunier P, Agapakis-Causse C. Mini mutagenicity test: A miniaturized version of the Ames test used in a prescreening assay for point mutagenesis assessment. Toxicol In Vitro 2001;15:105-14.
15. Kirsch-Volders M, Sofuni T, Aardema M, Albertini S, Eastmond D, Fenech M, et al. Report from the in vitro micronucleus assay working group. Mutat Res 2003;540:153-63.
16. Garriott ML, Phelps JB, Hoffman WP. A protocol for the in vitro micronucleus test. I. Contributions to the development of a protocol suitable for regulatory submissions from an examination of 16 chemicals with different mechanisms of action and different levels of activity. Mutat Res 2002;517:123-34.
17. Phelps JB, Garriott ML, Hoffman WP. A protocol for the in vitro micronucleus test. II. Contributions to the validation of a protocol suitable for regulatory submissions from an examination of 10 chemicals with different mechanisms of action and different levels of activity. Mutat Res 2002;521:103-12.
18. Parry JM, Parry EM. The use of the in vitro micronucleus assay to detect and assess the aneugenic activity of chemicals. Mutat Res 2006;607:5-8.
19. Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S, Zeiger E. HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 2003;534:65-75.
20. CEREP. Genetic Toxicity. . Accessed on November 1, 2006.
21. Schoonen WG, de Roos JA, Westerink WM, Debiton E. Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II. Mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol In Vitro 2005;19:491-503.
22. Schoonen WG, Westerink WM, de Roos JA, Debiton E. Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I. Mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol In Vitro 2005;19:505-16.
23. Mannerstrom M, Toimela T, Ylikomi T, Tahti H. The combined use of human neural and liver cell lines and mouse hepatocytes improves the predictability of the neurotoxicity of selected drugs. Toxicol Lett 2006;165:195-202.
24. Tokiwa T, Yamazaki T, Xin W, Sugae N, Noguchi M, Enosawa S, et al. Differentiation potential of an immortalized non-tumorigenic human liver epithelial cell line as liver progenitor cells. Cell Biol Int 2006;30:992-98.
25. Dambach DM, Andrews BA, Moulin F. New technologies and screening strategies for hepatotoxicity: Use of in vitro models. Toxicol Pathol 2005;33:17-26.
26. O'Brien P, Haskins JR. In vitro cytotoxicity assessment. Meth Mol Biol 2006; 356:415-26.
27. Jones PA, King AV. High throughput screening (HTS) for phototoxicity hazard using the in vitro 3T3 neutral red uptake assay. Toxicol In Vitro 2003;17:703-8.
28. NICEATM I. In vitro 3T3 NRU phototoxicity. . Accessed November 1, 2006.
29. NICEATM. NICEATM pre-screen evaluation of the in vitro endocrine disruptor assay (Robotic MCF-7 cell proliferation assay of estrogenic activity). . Accessed November 1, 2006.
30. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995;23:S16-24.
31. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: The reactive metabolite syndromes. Lancet 2000;356:1587-91.
32. Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Pirmohamed M. Metabolic activation in drug allergies. Toxicology 2001;158:11-23.
33. Chen WG, Zhang C, Avery MJ, Fouda HG. Reactive metabolite screen for reducing candidate attrition in drug discovery. Adv Exp Med Biol 2001;500:521-4.
34. Pearson PG, Threadgill MD, Howald WN, Baillie TA. Applications of tandem mass spectrometry to the characterization of derivatized glutathione conjugates: Studies with S-(N-methylcarbamoyl)glutathione, a metabolite of the antineoplastic agent N-methylformamide. Biomed Envir Mass Spectrom 1988;16:51-6.
35. Haroldsen PE, Reilly MH, Hughes H, Gaskell SJ, Porter CJ. Characterization of glutathione conjugates by fast atom bombardment/tandem mass spectrometry. Biomed Envir Mass Spectrom 1988;15:615-21.
36. Samuel K, Yin W, Stearns RA, Tang YS, Chaudhary AG, Jewell JP, et al. Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. J Mass Spectrom 2003;38:211-21.
37. Nelson SD. Structure toxicity relationships-How useful are they in predicting toxicities of new drugs? Adv Exp Med Biol 2001;500:33-43.
38. Casati S, Collotta A, Clothier R, Gribaldo L. Refinement of the colony-forming unit-megakaryocyte (CFU-MK) assay for its application to pharmaco-toxicological testing. Toxicol In Vitro 2003;17:69-75.
39. Kimber I, Pichowski JS, Betts CJ, Cumberbatch M, Basketter DA, Dearman RJ. Alternative approaches to the identification and characterization of chemical allergens. Toxicol In Vitro 2001;15:307-12.
40. Flick B, Klug S. Whole embryo culture: An important tool in developmental toxicology today. Curr Pharm Des 2006;12:1467-88.
41. Coecke S, Eskes C, Gartion J, Vliet EV, Kinsner A, Bogni A, et al. Metabolism-mediated neurotoxicity: the significance of genetically engineered cell lines and new three-dimensional cell cultures. Altern Lab Anim 2002;30(Suppl 2):115-18.
42. Prieto P. Barriers, nephrotoxicology and chronic testing in vitro. Altern Lab Anim 2002;30(Suppl 2):101-6.
43. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 2006;80:580-604.
44. Amacher DE, Martin B-A. Tetracycline-induced steatosis in primary canine hepa-tocyte cultures. Fund Appl Toxicol 1997;40:256-63.
45. Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, et al. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 2006;90:451-9.
46. Gum RJ, Hickman D, Fagerland JA, Heindel MA, Gagne GD, Schmidt JM, et al. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem Pharmacol 2001;62:1661-73.
47. Thompson DC, Barhoumi R, Burghard RC. Comparative toxicity of eugenol and its quinone methide metabolite in cultured liver cells using kinetic fluorescence bioassays. Toxicol Appl Pharmacol 1998;149:55-63.
48. Lilius H, Haestbacka T, Isomaa B. A combination of fluorescent probes for evaluation of cytotoxicity and toxic mechanisms in isolated rainbow trout hepatocytes. Toxicol In Vitro 1996;10:341-8.
49. LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 1992;5:227-31.
50. Lautraite S, Bigot-Lasserre D, Bars R, Carmichael N. Optimisation of cell-based assays for medium throughput screening of oxidative stress. Toxicol In Vitro 2003;17:207-20.
51. Wang H, Joseph JA. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 1999;27:612-16.
52. Haskins JR, Rowse P, Rahbari R, de la Iglesia FA. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch Toxicol 2001;75:425-38.
53. Tan NS, Michalik L, Desvergne B, Wahli W. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J Steroid Biochem Mol Biol 2005;93:99-105.
54. Xu D, McCarty D, Fernandes A, Fisher M, Samulski RJ, Juliano RL. Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther 2005;11:523-30.
55. Lee SH, Sinko PJ. siRNA-Getting the message out. Eur J Pharm Sci 2006;27:401-10.
56. Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 2005;11:4487-94.